Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595359 | 0.91 | TSHR (0.58) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL6017659 | 0.91 | TSHR (0.58) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL31612277 | 0.87 | ALDH1A1 (0.51) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL1589851 | 0.87 | ALDH1A1 (0.51) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL9488274 | 0.83 | TSHR (0.53) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL13520160 | 0.79 | ALDH1A1 (0.53) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL15380345 | 0.79 | TSHR (0.53) | TSHRALDH1A1SNCACYP1A2MAPT | |
| SCHEMBL29450341 | 0.79 | CYP1A2 (0.45) | ALDH1A1SNCACYP1A2MAPTPDK1 | |
| SCHEMBL26458399 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1SNCACYP1A2MAPTPDK1 | |
| SCHEMBL67536 | 0.79 | MAPK1 (0.53) | TSHRALDH1A1CYP1A2MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2021-06-08 | — | — | US | disclosed |
| EP-3441071-A1 | DERIVATIZED CEPHALOSPORINS | Gladius Pharmaceuticals Corporation (CA) | 2019-02-13 | — | — | EP | disclosed |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-11-08 | — | — | US | disclosed |
| EP-2968352-B1 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | GLADIUS PHARMACEUTICALS CORP (CA) | 2018-09-26 | — | — | EP | disclosed |
| US-9975905-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-05-22 | — | — | US | disclosed |
| US-9975905-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-05-22 | — | — | US | disclosed |
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SOPHARMIA, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SOPHARMIA, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SOPHARMIA, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2968352-A2 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | Gladius Pharmaceuticals Corporation (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165126-A2 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | SOPHARMIA, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SI, ENGASE, CMBL | TSHR 4621/4885ALDH1A1 338/4885SNCA 2282/4885 |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | PEPD, SI, NAALAD2 | TSHR 4568/4885ALDH1A1 210/4885SNCA 1989/4885 |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | PEPD, SI, NAALAD2 | TSHR 4568/4885ALDH1A1 210/4885SNCA 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.